Contributions of animal models of cognitive disorders to neuropsychopharmacology
- 3 February 2021
- journal article
- research article
- Published by Elsevier BV in Therapies
- Vol. 76 (2), 87-99
- https://doi.org/10.1016/j.therap.2021.02.001
Abstract
No abstract availableKeywords
This publication has 123 references indexed in Scilit:
- The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disordersBritish Journal of Pharmacology, 2013
- Prefrontal dopamine and behavioral flexibility: shifting from an “inverted-U” toward a family of functionsFrontiers in Neuroscience, 2013
- NMDA Receptor Activity in Neuropsychiatric DisordersFrontiers in Psychiatry, 2013
- Hypoxia. 3. Hypoxia and neurotransmitter synthesisAmerican Journal of Physiology-Cell Physiology, 2011
- Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin miceProceedings of the National Academy of Sciences of the United States of America, 2009
- The use of lentiviral vectors combined with Cre/loxP to investigate the function of genes in complex behaviorsFrontiers in Molecular Neuroscience, 2009
- Physostigmine Reverses Cognitive Dysfunction Caused by Moderate Hypoxia in Adult MiceAnesthesia & Analgesia, 2007
- Effects of sleep deprivation on neural functioning: an integrative reviewCellular and Molecular Life Sciences, 2007
- Abnormal Neurotransmitter Release Underlying Behavioral and Cognitive Disorders: Toward Concepts of Dynamic and Function-Specific DysregulationNeuropsychopharmacology, 2006
- Hypobaric hypoxia impairs spatial memory in an elevation-dependent fashionBehavioral and Neural Biology, 1994